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Background: Impairments of health related quality of life (HRQoL) are frequently observed in Fabry disease (FD)
and are known to be related to neuropathic pain and cardiovascular events. This study aimed to explore the role of
chronic kidney disease (CKD) in a large cohort of patients with FD.
Methods: In 96 patients (53% female; age 40 ± 12 yrs) with genetically proven FD, HRQoL was assessed by the
Medical Outcomes Study (SF-36) questionnaire. All patients were naïve to enzyme replacement therapy. Three
categories for kidney dysfunction were chosen, eGFR ≥/<60 ml/min/1.73 m2 or need of renal replacement therapy
(RRT). Minor (e.g. arrhythmia, angina pectoris, etc.) and major (e.g. myocardial infarction, coronary artery bypass,
stroke or implantable cardioverter-defibrillator) vascular events as well as pain and pain therapy were considered in
linear regression analyses with the dimensions of HRQoL.
Results: Ten patients (10%) had impaired kidney function and a further nine were on RRT (9.4%). Kidney function
and pain emerged as the main factors associated with lower scores on the SF 36, in particular on physical
components (PCS beta-coefficients for CKD −6.2, for RRT −11.8, for pain −9.1, p < 0.05, respectively), while
controlling for gender, vascular event and pain-therapy. Relationships were found for mental aspects of HRQoL.
Age and history of vascular events were not related to HRQoL.
Conclusion: Cardiovascular events and pain are important factors related to HRQoL, social functioning and
depression. Our study highlights impaired chronic kidney disease, in particular after initiation of RRT, as a strong
determinant of reduced HRQoL in FD.
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Fabry disease (FD) is a rare, X-linked lysosomal storage
disorder, which results from deficient activity of the en-
zyme α-galactosidase (α-Gal A) and progressive lysoso-
mal deposition of globotriaosylceramide (GL-3) in several
tissues and cells throughout the body [1]. In classically
affected males, cellular dysfunction leads to progres-
sive organ failure [2]. In heterozygous women onset of* Correspondence: johannes.kraemer@stud-mail.uni-wuerzburg.de
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unless otherwise stated.symptoms is frequently delayed, but can show a broad
variety of disease manifestation [3,4]. Early symptoms of
the disease include neuropathic pain (acroparaesthesia),
triggered by fever or physical exertion, hypohidrosis and
heat intolerance. Later stages are characterized by severe
organ involvement such as chronic kidney disease (CKD)
and end stage renal disease (ESRD), left ventricular hyper-
trophy and heart failure as well as cerebrovascular com-
plications. Further classical features are angiokeratoma,
corneal opacities, tinnitus, hearing loss and vertigo [2].
Management of the disease was primarily symptomatic
until enzyme replacement therapy (ERT) became available
for clinical use. Several clinical trials demonstrated the ef-
ficacy of ERT to prevent or slow serious organ dysfunctionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with more progressed disease had a less favourable out-
come. Impaired kidney function and overt proteinuria at
the time of institution of ERT emerged as an important
prognostic factor for the course of the disease [7].
Health Related Quality of Life (HRQoL) is a multidi-
mensional construct referring to patients’ perceptions of
the impact of disease and treatment on their physical,
psychological and social function and well being. HRQoL
questions about perceived physical and mental health and
function have become an important component of health
surveillance and are generally considered valid indicators
of service needs and intervention outcomes. In Fabry dis-
ease, patients suffer not only from the debilitating physical
symptoms, but also from a compromised HRQoL, which
is reported for both, males and females [8,9] Possible
underlying reasons are numerous, ranging from disease
related pain to vital organ dysfunction.
The purpose of the current study was to characterize
HRQoL as assessed by the SF-36® questionnaire in a large
cohort of patients with Fabry disease. We aimed to iden-
tify factors associated with the various dimensions of
physical and mental functioning, with a focus on kidney
function.
Methods
Study participants
Since June 2001, an increasing number of patients with
genetically proven Fabry disease from all over the country
are overseen at our hospital. In regular visits, physical
examination and detailed evaluation of medical history
and medications are performed by a trained nurse and a
physician. Furthermore, patients are enrolled in an inter-
national observational cohort study if they provided writ-
ten informed consent [10]. The local Ethics Committee of
the University of Würzburg approved the study. For the
current analyses, patients who had their first visit until
August 2009 were included, if they were older than 16
years with available data on HRQoL within three months
before or after the first visit. We analyzed data from the
first visit at our center, regardless of time since the diagno-
sis of Fabry disease or whether or not they were receiving
ERT at the time of enrollment.
Assessment of HRQoL
HRQoL was assessed by the Medical Outcomes Study
SF-36 questionnaire [11] at baseline and was repeated
after six months [2]. The SF-36 is a validated instrument
to describe HRQoL in a broad spectrum of diseases and
is widely used in clinical practice and clinical research
[12,13]. Patients respond to questions about activities of
daily life and physical and social well being, resulting in
two summary scales (physical component summary [PCS]
and mental component summary [MCS]) and eight scalesdescribing various physical and mental aspects (physical
and social functioning, physical and emotional role, bodily
pain, general and mental health, vitality). Each dimension
is displayed on a scale ranging from score 0 to 100, repre-
senting impaired vs. improved health [14].
Definitions
Glomerular filtration rate (eGFR) was estimated according
to the simplified Modification of Diet in Renal Disease for-
mula [15]. Stages of CKD were classified as eGFR ≥ 60 ml/
min/1.73 m2, eGFR < 60 ml/min/1.73 m2 and renal re-
placement therapy (RRT), i.e., dialysis or kidney trans-
plantation (KTx). History of arrhythmia, angina pectoris,
significant cardiac procedure without coronary stent
implantation, or transient ischemic attack (TIA) was
considered as minor vascular event, whereas history of
myocardial infarction, coronary stent implantation, cor-
onary artery bypass, stroke or implantable cardioverter-
defibrillator (ICD) were described as major vascular
event. Pain was assessed by using the visual analog
scale (VAS), ranging from no pain (score 0) to maximal
pain (score 10). Patient’s pain therapy (i.e. frequent use
of analgetics) was not altered.
Statistical methods
Analyses were performed using SAS 9.1 (SAS Institute,
Cary, NC). Characteristics of study participants and the
different scales of HRQoL were compared across CKD
stages using ANOVA, Kruskal-Wallis test, χ2- test, and
Fisher’s exact test, as appropriate. Factors associated with
the various dimensions of HRQoL were examined using
linear regression analysis. To assure a linear relationship
with the dependent variable, the logarithmic form was
used for “time since Fabry diagnosis”. In multivariate ana-
lyses, the following variables were included in the model;
age, gender, kidney function, vascular event, pain and
pain-therapy. We investigated the relationship between
pain and HRQoL according to their interaction with
pain-therapy. Notably, the variable “enzyme replacement
therapy, initiated within three months following the first
visit” was not considered as a risk factor for HRQoL since
impaired physical and mental status of the patient repre-
sents the cause of initiating ERT; i.e., the variable can be
seen as a measure of “sickness” and does not describe the
effect of ERT.
The robustness of the results was further evaluated by
(1) including only four variables in the multivariate mo-
del, to minimize the risk of observing potential asso-
ciations by chance due to a large number of candidate
variables (“overfitting”). Thus, the least significant vari-
able was ignored; (2) including patients in whom data of
the SF-36 was available within nine months prior or fol-
lowing the first visit (three additional patients); (3) con-
sidering kidney transplant recipients (n = 2) not in the
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spective CKD category; (4) not differentiating between
minor and major CV events, but including CV events as
a single category.Results
Study population
Ninety-six patients older than 16 years of fifty-two fam-
ilies were treated at our center between June 2001 and
August 2009. The mean age of the cohort was 40 yrs,
47% were male, and the diagnosis of Fabry disease was
made a median time of nine months prior to the first
visit. All patients were naïve to ERT. Characteristics of
study participants stratified by kidney function are dis-
played in Table 1. Most of the patients, in particular most
women, had preserved kidney function, whereas patients
with impaired kidney function were more likely to be
male. All patients receiving RRT were of male gender
(n = 9), of whom two underwent kidney transplantation
and seven received dialysis. Minor vascular events were
also more common in patients with CKD, as was a his-
tory of major vascular events. Furthermore, patients with
impaired kidney function, in particular those receiving
RRT, were more likely to be initiated on ERT within three
months following the study visit. Written informed con-
sent was obtained for participation and publication of cli-
nical and individual data.Table 1 Characteristics of study participants, stratified by kid
eGFR ≥60 ml/min/1.73 m2 n = 77 eGFR
Age, yrs 38.8 ± 13.1
Male gender 39.1 %
Diagnosis Fabry disease, months 9 (6; 14)
Enzyme replacement therapya 37.7 %
BMI, kg/m2 22.4 (20.8; 24.9)
Systolic blood pressure, mmHg 118 ± 15
Diastolic blood pressure, mmHg 75 ± 10
eGFR, ml/min/1.73 m2 96 (83; 110)
Vascular event
Minorb 13.2 %
Majorc 4.0 %
Pain 44.3 %
Pain therapy 18.8 %
VASd 2 (1; 3)
Data are means (± SD), medians (IQR) or proportions; comparison across CKD stage
abbreviations: eGFR estimated glomerular filtration rate as assessed by the abbrevia
therapy (dialysis, or kidney transplantation [KTx]), BMI body mass index; VAS, visual
aInitiation of enzyme replacement therapy within the first three months following t
bHistory of transient ischemic attack (TIA), angina pectoris, significant cardiac proce
cHistory of stroke, myocardial infarction, coronary stent, coronary bypass surgery, IC
dMedian pain according to the visual analog scale during the three months precedHealth related quality of life
Data on HRQoL were missing in six patients, and in
three additional patients the SF-36 was not completed
within three months following the first visit, thus leav-
ing eighty-six patients for further analyses (Table 2). Of
note, all patients with missing HRQoL had preserved
kidney function. Chronic kidney disease was generally
associated with reduced HRQoL. More specifically, lower
scores on dimensions of mental health, as represented by
social functioning, role emotional, mental health, and the
MCS, were observed in patients dependent on RRT. In
contrast, physical aspects, such as physical functioning,
role physical, bodily pain, and the PCS, were affected even
in patients with moderately impaired kidney function, i.e.,
eGFR < 60 ml/min.
Determinants of health related quality of life
Similar to the described findings, impaired kidney func-
tion, particularly the need of RRT, was associated with
markedly reduced HRQoL across all scales in univariate
linear regression analysis (Tables 3a and b). Furthermore,
male gender, pain and pain-therapy were significantly and
meaningfully associated with lower scores on the SF-36
scales, except general and mental health. Age and a his-
tory of vascular events, neither minor nor major events,
were not found to be related to HRQoL. This is shown in
detail in Additional file 1. In multivariate modeling, im-
paired kidney function and pain emerged as the mainney function
<60 ml/min/1.73 m2 n = 10 RRT (dialysis or KTx) n = 9 p-value
53.0 ± 11.3 37.0 ± 8.6 0.004
60.0 % 100.0 % 0.002
12 (8; 22) 14 (7; 94) 0.31
60.0 % 88.9 % 0.01
23.6 (20.9; 30.8) 21.9 (19.9; 24.4) 0.36
133 ± 21 131 ± 25 0.01
81 ± 14 81 ± 9 0.07
37 (25; 45) dialysis 7 (5; 13) KTx 37 (19; 54) <0.001
0.05
40.0 % 22.2 %
10.0 % 0 %
77.8 % 71.4 % 0.08
60.0 % 62.5 % 0.002
2 (0; 3) 2 (2; 3) 0.46
s using ANOVA, Kruskal-Wallis test, χ2- test or Fisher’s exact test, as appropriate;
ted modification of diet in renal disease (MDRD) formula, RRT renal replacement
analog scale.
he first visit.
dure without coronary stent, arrhythmia.
D-implantation.
ing the first visit in patients reporting pain.
Table 2 Health related quality of life (SF-36), stratified by kidney function
eGFR >60 ml/min/1.73 m2 n = 66 eGFR <60 ml/min/1.73 m2 n = 10 RRT (dialysis or KTx) n = 9 p-value
Physical functioning 85 (65; 100) 52.5 (25; 75) 50 (30; 55) <0.001
Role physical 100 (25; 100) 37.5 (0; 100) 0 (0; 37.5) 0.004
Bodily pain 68 (51; 100) 41 (41; 64) 22 (12; 51) 0.004
General health 57 (46; 79.5) 45 (35; 52) 25 (17; 40) <0.001
Vitality 52.5 (32.5; 65) 40 (30; 50) 30 (5; 30) 0.01
Social functioning 87.5 (62.5; 100) 75 (50; 100) 25 (25; 50) <0.001
Role emotional 100 (66.7; 100) 100 (0; 100) 33.3 (0; 33.3) 0.008
Mental health 66 (52; 80) 64 (52; 76) 44 (28; 60) 0.08
Physical component summary 49.8 (37.7; 54.7) 35.9 (24.8; 44.4) 29.4 (25.0; 35.5) <0.001
Mental component summary 47.1 (41.5; 54.5) 49.8 (35.4; 56.3) 30.1 (24.5; 34.9) 0.01
Data are means (± SD), medians (IQR); comparisons across CKD-stages using Kruskal-Wallis test; abbreviations: eGFR estimated glomerular filtration rate according
to the modification of diet in renal disease formula, RRT renal replacement therapy (dialysis, or kidney transplantation [KTx]).
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particular on dimensions of physical aspects of life, such
as physical functioning, role physical, bodily pain, general
health and the PCS, while controlling for gender, vascular
event and pain-therapy. In contrast, only the need for
RRT was found to be associated with reduced HRQoL in
mental/social parameter dimensions, when adjusting for
the described variables. By including the respective in-
teraction term, we tested whether the relationship of
pain and HRQoL was altered by pain-therapy. Being on
pain-therapy, but still suffering from pain was related
to even lower scores on the role physical-scale (p = 0.001),
while this finding approached significance in bodily
pain (p = 0.06), role emotional (p = 0.08) and the PCS
(p = 0.07). The variables included in the multivariate mo-
dels explained a median of 35% (min.-max; 10-52%) of the
variability in the respective SF-36 scale.
We tested the robustness of our results in a first step
by including only four explanatory variables in the multi-
variate linear regression model. Excluding vascular event,
which represented the least significant variable, did not re-
sult in significant changes of our findings, neither on the
magnitude of the direction, nor on the significance levels
or the respective variables. Similarly, by including three
additional patients in whom the SF-36 was completed
within nine months prior or following the study visit, no
significant changes in the estimates of the variables in the
multivariate model were found; however, the 95% CI be-
came narrower, resulting in pain-therapy being significant
on the p < 0.05 level in the physical functioning scale.
Moreover, when we analyzed the two KTx-patients in the
respective eGFR category, i.e., excluding them from the
RRT category, we did not detect major differences in the
findings, except in the variable describing kidney function.
Generally, the associations of RRT with the respective
scales strengthened including narrower 95% CI in physical
aspects, such as physical functioning, role physical andemotional, and the PCS. No changes were observed in
mental parameters. Details are shown in Additional file 1.
Finally, treating CV-events in a single category did also
not alter the results: neither became the variable CV-
event significant, nor did the associations of the remaining
determinants in the model substantially change. Add-
itional file 1 shows this in more detail.
Discussion
Chronic kidney disease was generally associated with re-
duced HRQoL, especially mental health, as represented
by social functioning, role emotional, and the MCS. In
contrast, physical aspects, such as physical functioning,
role physical, bodily pain, and the PCS, were affected
even in patients with moderately impaired kidney func-
tion. Impaired kidney function, particularly the need of
RRT, was associated with markedly reduced HRQoL
across all scales in univariate linear regression analysis.
A number of studies investigated Quality of life in pa-
tients with Fabry disease. Most studies constrain to com-
parisons with healthy controls which indicate major
impairments in affected patients [8,9,16,17] and the effects
of enzyme replacement therapy on HRQoL. If SF-36 ques-
tionnaires were used, the main affected parameter was
‘general health’ [9]. Moreover, psychiatric diseases and re-
lated affections of HRQoL are frequently evident in Fabry
patients [18]. Data from the Fabry outcome survey showed
reduced values for EQ-5D in FD compared to healthy
controls and other diseases like lung cancer, kidney and
liver transplantation [19]. Improvements of HRQoL were
also reported after 12 months of ERT. [17,20-22], although
it is not completely understood, how treatment directly
improves quality of life. None of the studies reported the
HRQoL according to specific organ dysfunction. Chronic
neuropathic pain is still regarded as one of the most dif-
ficult aspects of Fabry's disease for patients. Its effect
on HRQoL is still regarded larger than cardiac and renal
Table 3 Risk factors for HRQoL, linear regression model
Physical functioning Role physical Bodily pain General health
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
Age (year) −0.1 (−0.5; 0.4) -- −0.2 (−1.0; 0.6) -- 0.3 (−0.3; 0.8) -- −0.03 (−0.4; 0.4) --
Gender (male) −14.8 (−25.6; −4.0) −1.7 (−12.1; 8.6) −33.2 (−51.6; −14.9) −17.1 (−37.1; 2.9) −18.1 (−31.9; −4.3) 0.1 (−13.1; 13.2) −21.6 (−30.8; −12.4) −12.4 (−22.7; −2.1)
Diagnosis (month)a −2.4 (−6.8; 1.9) -- 0.1 (−7.6; 7.8) -- 0.3 (−5.3; 5.9) -- −3.3 (−7.2; 0.73) --
Kidney functionb
<60 vs. >60 ml/min/
1.73 m2
−25.6 (−39.8; −11.4) −16.3 (−29.9; −2.7) −25.1 (−52.6; 2.5) −14.8 (−41.1; 11.4) −14.0 (−33.7; 5.7) −0.9 (−18.1; 16.3) −15.8 (−29.4; −2.1) −9.3 (−22.7; 4.1)
RRT vs. >60 ml/min/
1.73 m2
−31.9 (−46.7; −17.0) −22.7 (−39.6; −5.9) −48.2 (−78.6; −17.8) −34.1 (−66.6; −1.5) −36.3 (−57.0; −15.6) −32.5 (−53.8; −11.2) −32.3 (−46.7; −18.0) −28.8 (−45.4; −12.2)
Vascular event
Minorc −4.4 (−17.7; 8.9) 4.3 (−7.2; 15.8) −9,5 (−33.7; 14.6) −10.5 (−32.7; 11.7) −9.1 (−26.3; 8.0) −2.6 (−17.1; 11.9) −10.3 (−23.0; 2.5) −6.6 (−18.4; 5.1)
Majord 10.2 (−18.0; 38.3) 18.4 (−3.7; 40.6) 2.4 (−48.6; 53.4) 19.1 (−23.6; 61.8) 18.3 (−18.0; 54.7) 24.6 (−3.4; 52.5) −12.8 (−39.1; 13.5) −5.0 (−26.7; 16.8)
Pain −23.3 (−23.3; −13.3) −14.4 (−24.4; −4.4) −37.7 (−56.3; −19.1) −19.9 (−39.2; −0.6) −37.2 (−49.6; −24.8) −28.9 (−41.6; −16.3) −22.2 (−32.4; −12.2) −12.5 (−22.6; −2.5)
Pain-therapy −20.1 (−32.1; −8.1) −10.4 (−22.0; 1.1) −38.8 (−58.6; −18.0) −16.4 (−38.6; 5.8) −26.0 (−40.9; −11.1) −10.3 (−24.8; 4.3) −19.2 (−30.3; −8.1) −2.8 (−14.2; 8.7)
Vitality Social functioning Role emotional Mental health
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
Age (year) −0.1 (−0.5; 0.3) -- −0.1 (−0.6; 0.4) -- −0.5 (−1.2; 0.2) -- −0.1 (−0.4; 0.3) --
Gender (male) −12.1 (−22.3; −1.9) 0.5 (−10.6; 11.6) −18.2 (−29.8; −6.5) −4.2 (−15.6; 7.2) −22.8 (−40.1; −5.5) −8.6 (−26.9; 9.8) −7.7 (−16.1; 0.8) −0.9 (−10.3; 8.5)
Diagnosis (month)a −1.1 (−5.2; 3.1) -- 0.3 (−4.5; 5.1) -- −4.6 (−11.6; 2.3) -- 0.7 (−2.7; 4.0 ) --
Kidney functionb
<60 vs. >60 ml/min/
1.73 m2
−6.7 (−21.1; 7.7) −1.5 (−15.9; 13.0) −3.9 (−19.6; 12.1) 3.0 (−11.9; 18.0) −15.6 (−40.1; 8.8) −6.6 (−30.4; 17.2) −2.0 (−14.0; 10.1) 1.9 (−10.4; 14.2)
RRT vs. >60 ml/min/
1.73 m2
−25.3 (−40.4; −10.2) −24.5 (−42.4; −6.6) −41.5 (−58.3; −24.7) −46.2 (−64.7; −27.6) −45.7 (−71.3; −20.0) −45.0 (−74.6; −15.5) −17.4 (−30.0; −4.8) −15.8 (−31.0; −0.6)
Vascular event
Minorc −1.0 (−13.8; 11.9) −0.7 (−13.4; 12.0) −0.66 (−15.5; 14.2) 0.5 (−12.1; 13.2) −4.1 (−25.6; 17.5) 0.4 (−19.7; 20.5) −3.0 (−13.6; 7.6) −1.5 (−12.3; 9.3)
Majord −13.0 (−39.5; 13.5) −14.1 (−37.7; 9.4) 10.8 (−20.7; 42.3) 11.2 (−13.1; 35.6) 5.0 (−40.7; 50.6) 7.2 (−31.6; 46.0) −5.1 (−26.9; 16.7) −5.4 (−25.4; 14.6)
Pain −19.8 (−29.7; −10.0) −14.8 (−25.7; −3.9) −20.0 (−31.8; −8.2) −9.3 (−20.3; 1.8) −20.8 (−38.1; −3.5) −5.1 (−22.8; 12.6) −8.1 (−16.7; 0.5) −1.6 (−10.9; 7.6)
Pain-therapy −10.2 (−21.9; 1.4) −0.6 (−13.0; 11.7) −14.6 (−28.1; −1.1) −7.6 (−20.3; 5.1) −14.6 (−34.6; 5.3) −8.1 (−28.4; 12.2) −6.6 (−16.0; 2.8) −4.8 (−15.3; 5.6)
Physical component summary Mental component summary
Univariate Multivariate Univariate Multivariate
Age (year) 0.03 (−0.2; 0.2) -- −0.1 (−0.39; 0.1) --
Male gender −8.9 (−13.8; −4.0) −2.4 (−7.3; 2.5) −4.9 (−9.8; −0.02) −0.2 (−6.2; 4.5)
Diagnosis (month)a −0.6 (−2.7; 1.4) -- −0.3 (−2.2; 1.7) --
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Table 3 Risk factors for HRQoL, linear regression model (Continued)
Kidney functionb
<60 vs. >60 ml/min/1.73 m2 −10.4 (−17.3; −3.4) −6.2 (−12.5; 0.1) 1.1 (−5.7; 7.9) 2.8 (3.5; −4.1)
RRT vs. >60 ml/min/1.73 m2 −16.0 (−23.7; −8,4) −11.8 (−19.6; −4.0) −14.3 (−21.8; −6.8) −13.3 (−21.8; −4.7)
Vascular event
Minorc −2.9 (−9.5; 3.7) −0.1 (−5.5; 5.4) −0.6 (−6.8; 5.6) −1.1 (−7.1; 4.9)
Majord 3.3 (−10.3; 16.8) 8.2 (−2.0; 18.4) −1.1 (−13.9; 11.7) −3.4 (−14.6; 7.8)
Pain −14.3 (−18.9; −9.7) −9.1 (−13.8; −4.3) −4.1 (−9.0; 0.9) −1.1 (−6.3; 4.1)
Pain-therapy −12.2 (−17.7; 6.8) −5.5 (−10.9; −0.1) −1.8 (−7.4; 3.7) −0.4 (−6.3; 5.6)
Data are beta-coefficients with respective 95% confidence interval (CI), significant values (p < 0.05) bolded.
aDiagnosis Fabry disease, logarithmic form.
bPatient with kidney transplantation classified as RRT.
cHistory of transient ischemic attack (TIA), angina pectoris, significant cardiac procedure without coronary stent, arrhythmia.
dHistory of stroke, myocardial infarction, coronary stent, coronary bypass surgery, ICD-implantation.
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http://www.biomedcentral.com/1471-2369/15/188disease [23]. The long-term complications in kidney, heart
and brain lead to renal failure, cardiomyopathy, and strokes
in adults, respectively and are all well known to impact on
patients’ wellbeing and social function in various magni-
tude. However, in our study, the history of minor of major
vascular events including stroke or cardiac complications
was not significantly associated with HRQoL.
We found that chronic kidney disease, although im-
paired kidney function and its progression is deemed to
be apparently asymptomatic, was an important deter-
minant of the patients’ wellbeing which is a crucial fac-
tor for reduced HRQoL in physical and mental and
social aspects of life. Among the SF-36, reduced kidney
function was connected to reduced values in all eight
items, mainly affecting physical role (univariate −48.2
(−78.6; −17,8)) and social functioning (univariate −41.5
(−58.3; 24.7)) which is considered as clinically meaning-
ful [24]. While in particular the need of RRT was asso-
ciated with dramatic impairments of all aspects of
HRQoL, even non-dialysis-dependent CKD was related
to lower scores in physical dimensions. These findings
were evident, however somewhat attenuated, after con-
trolling for clinical variables including male gender.
Major therapeutic components of Fabry disease pa-
tients focus on pain medication and mental coping, in-
cluding modifications of daily life activities and behavior.
Suffering from pain naturally can be seen as causal for
reductionsin social and physical functioning. In our ana-
lyses it was interesting that being on specific-medication,
but still suffering from pain was related to even lower
scores on the role physical-scale, while this finding ap-
proached significance in bodily pain, role emotional and
the PCS.This might either be caused by a higher level of
pain which is pledged to analgetics to reach a bearable
level but is still affecting quality of life, or might be con-
nected to the additional negative effect of destitution by
ineffective pain medication.
It has been suggested by various studies [8,9] that a
history of cardiovascular disease impacts on HRQoL in
Fabry patients. We categorized cardiovascular events
into minor and major events and found that neither was
significantly associated with HRQoL in univariate or
multivariate analyses, respectively. Besides that our data
show the importance of kidney function which was not
addressed in previous studies.
In contrast, in a large analysis of Fabry patients in
Canada [25], patients had more neurological events, more
cardiac events and more often pain to an extent that made
them candidate for enzyme therapy. The fact that data of
our cohort were analyzed at the patients’ first visit in our
centre, and were also slightly younger (40 ± 13 yrs) than
the cohort by Sirrs et al. (48 ± 16 yrs), might be the rea-
son for out cohort reporting a history of CV-events less
frequently. However, the absolute frequency of vascularevents of about 10-20% and frequency of pain in 70% is
fairly common in Fabry disease (FOS - Fabry outcome
survey) [26].
Our findings indicate that kidney disease in FD should
be consideredwhen aiming for improvements of HRQoL.
Aside from enzyme replacement therapy, optimal treat-
ment of kidney disease aiming to slow the progression of
CKD and an effective pain therapy may help to improve
HRQoL in Fabry patients.
Limitations
We are aware of several limitations of our findings. As
in any observational study, no relationship can be deter-
mined sufficiently, i.e., the direction of an association in
cross-sectional analyses cannot be explored. It would also
be desirable to investigate the changes in HRQoL in FD
patients and how these may be associated with changes in
renal function, optimized pain therapy, the occurrence of
vascular events, but also with the potential effects of ERT.
Moreover, the differentiation of pain severity according to
receiving or not receiving therapy for neurogenic pain is
diffuse, because it may depend on differences in percep-
tion of pain but also on differences in patient care. Besides
that, an influence of pain peaks, which are not detected by
the use of the VAS at one single point of time, on HRQoL
is not excluded.
Conclusions
Cardiovascular events and neuropathic pain have been
considered as solely being responsible for reduced qual-
ity of life, depression as well as reduced social function-
ing. Our study highlights chronic kidney disease, in
particular after initiation of RRT, but even early in dis-
ease progression, as a strong determinant of reduced
HRQoL in Fabry’s disease.
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